Compare TEVA & PRU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TEVA | PRU |
|---|---|---|
| Founded | 1901 | 1875 |
| Country | Israel | United States |
| Employees | 32842 | 36824 |
| Industry | Biotechnology: Pharmaceutical Preparations | Life Insurance |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.7B | 32.1B |
| IPO Year | N/A | N/A |
| Metric | TEVA | PRU |
|---|---|---|
| Price | $28.55 | $92.57 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 11 |
| Target Price | $37.38 | ★ $115.20 |
| AVG Volume (30 Days) | ★ 6.3M | 2.0M |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 6.05% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.51 | $3.00 |
| P/E Ratio | $28.19 | ★ $10.44 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.47 | $90.38 |
| 52 Week High | $37.35 | $119.76 |
| Indicator | TEVA | PRU |
|---|---|---|
| Relative Strength Index (RSI) | 31.56 | 34.77 |
| Support Level | $28.38 | $91.89 |
| Resistance Level | $31.99 | $105.81 |
| Average True Range (ATR) | 1.03 | 2.07 |
| MACD | -0.27 | -0.01 |
| Stochastic Oscillator | 6.81 | 15.97 |
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Prudential Financial is one of the largest US life insurers, offering annuities, life insurance, and asset-management products. The United States and Japan are its two largest markets. Its US business contributed about 50% of adjusted 2024 earnings and includes institutional retirement (mostly pension risk transfer), individual retirement (annuities), group insurance, and individual life insurance. Its international business represented about 40% of adjusted earnings, with a strong market position in Japan, and the firm also has a presence in emerging markets like Brazil. The company's investment management business, PGIM, contributed approximately 10% of its 2024 adjusted earnings. PGIM had around $1.4 trillion in assets under management at the end of third-quarter 2025.